Merck KGaA, Darmstadt GermanyPegylated TherapiesSelecting a CDMO for Custom Activated PEGsThis article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential … more ➔
Oncology ResearchTiny Models, Big ImpactOrganoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric … more ➔
BIMOVIS GmbHBIMOVISUnlock the Power of Structural BiologyIn this interview Dr. Martin Stieler, founder and CEO of BIMOVIS, introduces his company and the importance of structural biology in biotech and pharmaceutical industries, and highlights how BIMOVIS … more ➔
Indivumed GmbHDrug DiscoveryEvolving Antibody Innovation: New frontiers in cancer R&DFifty years after the invention of hybridoma technology, biologics have become a cornerstone of oncology drug discovery and development. From the first monoclonal antibody approval in 1995 to today’s … more ➔
T3 PharmaceuticalsBasel AreaHow T3 scaled faster in Basel’s biotech labsT3 Pharmaceuticals shows how a biotech can move from first experiments to a major international deal keeping pace – and roots – in the Basel Area. The team built, tested and scaled inside Switzerland … more ➔
Celonic GroupAllianceCelonic’s Strategic Alliance in ADCsThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s … more ➔
Wien-Tourismus/Christian-StemperBiotech clustersVienna: The centre of the European biotech worldThis year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here … more ➔
Rezon BioRezon BioMeeting global market challengesThe global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based … more ➔
Gene TherapyInnovative Approaches to Gene TherapyWatch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age … more ➔
Whitepaper Digital ManufacturingTackling 5 Key Challenges in Annex 11 and MHRA ReadinessDownload the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies … more ➔
Merck KGaA, Darmstadt Germany
BIMOVIS GmbH![Approvals of antibody-based therapies have accelerated sharply since 2000 with oncology dominating the landscape, newer modalities like ADCs and bispecifics gaining momentum [2]](https://european-biotechnology.com/wp-content/uploads/2025/10/Seite-71_EB325_Indivumed_Grafik1_RZ_X3-300x169.png)
Indivumed GmbH
T3 Pharmaceuticals
Celonic Group
Wien-Tourismus/Christian-Stemper
Rezon Bio
